Editas Medicine price target lowered to $7 from $9 at Wells Fargo
The Fly

Editas Medicine price target lowered to $7 from $9 at Wells Fargo

Wells Fargo lowered the firm’s price target on Editas Medicine (EDIT) to $7 from $9 and keeps an Overweight rating on the shares. The firm continues to see Editas’ focus on in vivo HSPC editing as a more effective use of its expertise and resources to create value. Wells looks forward to the next in vivo pipeline update in Q1 2025 as well as updates on reni-cel BD activity.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App